Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px

Document › Details

Rentschler Biopharma SE. (11/6/19). "Press Release: Rentschler Biopharma Kicks off Expansion at U.S. Facility in the Boston Biotech Hub". Laupheim & Milford, MA.

	Organisation	Rentschler Biopharma Inc.
	Group	Rentschler (Group)
	Organisation 2	GE Healthcare
	Group	General Electric (Group)
	Product	contract manufacturing (biologicals)
	Product 2	Xcellerex™ XDR-500 single-use bioreactor
	Index term	Rentschler–General Electric: single-use bioreactor, 201911–202006 supply Xcellerex XDR-500 bioreactor for Rentschler facility in Milford, MA
	Person	Zurdo, Jesús (Rentschler 201911 SVP Innovation + Venture Partnerships)
	Person 2	Pollano, Federico (Rentschler 201803– SVP BusDev before Polpharma Biologics + Richter-Helm + BioGeneriX)

>New 500 L bioreactor in operation mid-2020 at U.S. site

> Company’s clinical and commercial manufacturing capabilities to be showcased during BIO-Europe, November 11-13 in Hamburg, Germany

Rentschler Biopharma SE, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals, is taking the first step in the expansion project to grow its U.S. footprint and establish a Center of Excellence in North America, putting into operation a single-use bioreactor for the 93,000 square foot facility in Milford, MA, in the Greater Boston area.

The XDR-500 bioreactor, with a working volume of 100-500 L and down stream process capabilities of 2-8 g/L, is part of the state-of-the-art GMP facility suite concept. The system is planned to be client-ready in mid-2020 and is currently being prepared for technology transfer. With its innovative and highly flexible business model, the Milford site is already taking on new projects, including complex and difficult-to-manufacture proteins, e.g. multispecific antibodies.

Further expansion planning includes another building for large-scale manufacturing, which will also be single-use bioreactor manufacturing as well as lab capacity for new modalities. Both, in Europe and the U.S., Rentschler Biopharma will be able to leverage its client-centric approach and expertise in advanced technologies to facilitate the robust and scalable production of complex biomolecules.

Dr. Jesús Zurdo, Senior Vice President Innovation and Venture Partnerships, will bring to BIO-Europe® Rentschler Biopharma's knowledge and dedication to science as a foundation to convert medical research into outstanding biopharmaceuticals. In the workshop "Smart Drug Discovery", Dr. Zurdo, together with other experienced executives, will discuss the implementation of the best business models and technological innovations to follow the most efficient path in new drug development, including innovative manufacturing solutions.

Rentschler Biopharma events at Bio-Europe:

> Dr. Jesús Zurdo, Senior Vice President Innovation and Venture Partnerships, will address speed to clinic, fit for purpose development and early risk assessment as part of the workshop "Smart Drug Discovery": November 11, at 9:00 AM, Level 1, Hall B1, Room 6

> Exhibit Hall Hospitality Reception, November 12, 5:45 PM, Hall B2, Booth 53

> Federico Pollano, Senior Vice President Business Development, and his team are looking forward to meeting with you at the Rentschler Biopharma booth (#53, Hall B2)

About BIO-Europe

BIO-Europe is the preeminent partnering conference of the European life science industry, bringing together international decision makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities and private one-to-one meetings. The BIO-Europe® 2019 partnering event is expected to bring together 4,400 executives from more than 2,300 life sciences companies from over 60 countries. To learn more about the conference, please visitwww.ebdgroup.com/bioeurope.

Contact Person:

Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication
communications@rentschler-biopharma.com

Record changed: 2019-11-14